ImmuPharma plc (AIM:IMM)

Market Cap	11.99M
Revenue (ttm)	n/a
Net Income (ttm)	-2.48M
Shares Out	499.72M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,623
Average Volume	1,979,573
Open	2.396
Previous Close	2.415
Day's Range	2.271 - 2.490
52-Week Range	0.850 - 7.400
Beta	2.61
RSI	41.46
Earnings Date	Aug 5, 2025

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: IMM